Agora, Uromonitor® é digital.
Uma nova tecnologia para uma vigilância mais inteligente do NMIBC
Uma nova tecnologia para uma vigilância mais inteligente do NMIBC
We are proud to announce that the recent clinical study titled “Uromonitor: Clinical Validation and Performance Assessment of a Urinary Biomarker Within the Surveillance of Patients With Nonmuscle-Invasive Bladder Cancer”, led by Dr. Pedro Ramos et al., has been selected as Editor’s Choice in the March 2025 edition of The Journal of Urology®. This prestigious recognition… Read more »
A recent systematic review and meta-analysis evaluated the performance of Uromonitor®, a urine-based biomarker test for non–muscle-invasive bladder cancer (NMIBC). Analyzing 1,190 tests across four studies, Uromonitor® achieved 80.2% sensitivity, 96.9% specificity, and a high negative predictive value (96.6%). Compared to urinary cytology, Uromonitor® significantly improved sensitivity and test accuracy, reducing unnecessary cystoscopies by up… Read more »
A recent clinical study has confirmed the effectiveness of Uromonitor, an innovative urinary biomarker for the surveillance of nonmuscle-invasive bladder cancer (NMIBC). In a cohort of 439 patients with 528 surveillance episodes, the study demonstrated a sensitivity of 87% and specificity of 99%, along with a negative predictive value of 99%. These results confirm Uromonitor®’s eliability… Read more »
Uromonitor®: Reducing Unnecessary Cystoscopies and TURBT Procedures Non-muscle-invasive bladder cancer (NMIBC) follow-up relies on frequent cystoscopies, which are invasive, costly, and uncomfortable. Uromonitor® is a non-invasive urine test that detects NMIBC recurrence with high accuracy, significantly reducing unnecessary procedures. Fewer Cystoscopies – Uromonitor® could have prevented 87.4% of unnecessary cystoscopies, reducing patient discomfort and healthcare… Read more »
Uromonitor-V2®: A Breakthrough in NMIBC Surveillance Bladder cancer (BCa) requires lifelong monitoring, but traditional methods like cystoscopy and urine cytology are invasive, costly, and often lack sensitivity. Uromonitor-V2® is a non-invasive urine test that detects TERT, FGFR3, and KRAS mutations using real-time qPCR. Clinically validated, it outperforms urine cytology with 93.1% sensitivity and 85.4% specificity,… Read more »
Uromonitor test was recognized and considered by the scientific community as an excellent alternative for the non-invasive follow-up of patients previously diagnosed with Non-Muscle Invasive Bladder Cancer in a scientific article that was issue cover in an recognized international journal (Diagnostics). The details of this study can be found at: https://www.mdpi.com/2075-4418/10/1/39/htm
Concerned about the postponement of surveillance procedures and the increased risk of contamination in Hospitals, a team of researchers from Ipatimup and the Institute for Research and Innovation in Health (i3S) validated a new form of bladder cancer surveillance that, from now on, may be carried-out from home. Bladder cancer mainly affects smoking men over… Read more »
The Uromonitor test was recently validated by the scientific community in a international recognized peer-reviewed journal (Frontiers in Genetics) in a multicentric study comprising more than 300 human samples. Uromonitor presented high sensitivity (74%) and specificity (93%) in the detection of recurrence in patients under Follow-up for Non-Muscle Invasive Bladder Cancer. The details of this… Read more »
The test is currently performed as a service at Uromonitor, hosted at the above mentioned institutions.
To access the service, urologists in hospitals and clinics should first have materials for urine collection and shipment.
Direct ordering the complete analysis kit to be performed in a laboratory or medical unit.
Recommended for professionals!
“For persons at risk or patients diagnosed with bladder cancer, as well as their urologist, who have the need of more convenient surveillance methods, Uromonitor is a completely non-invasive, urine-based, In vitro Diagnosis (IVD) kit that is able to detect bladder cancer with high sensitivity and specificity.
Uromonitor is easy and can deliver reliable results to reduce costs with follow-up”.